0.34
-0.0205(-5.69%)
Currency In USD
| Previous Close | 0.36 |
| Open | 0.35 |
| Day High | 0.37 |
| Day Low | 0.34 |
| 52-Week High | 2.79 |
| 52-Week Low | 0.21 |
| Volume | 509,774 |
| Average Volume | 9.95M |
| Market Cap | 24.46M |
| PE | -0.25 |
| EPS | -1.34 |
| Moving Average 50 Days | 0.54 |
| Moving Average 200 Days | 1.12 |
| Change | -0.02 |
If you invested $1000 in IO Biotech, Inc. (IOBT) since IPO date, it would be worth $21.73 as of February 21, 2026 at a share price of $0.34. Whereas If you bought $1000 worth of IO Biotech, Inc. (IOBT) shares 3 years ago, it would be worth $126.87 as of February 21, 2026 at a share price of $0.34.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
IO Biotech Provides Corporate Update
GlobeNewswire Inc.
Jan 30, 2026 1:05 PM GMT
Raymond James engaged as financial advisorReduction in force implemented NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeut
IO Biotech Announces Exploration of Strategic Alternatives
GlobeNewswire Inc.
Jan 21, 2026 10:30 AM GMT
NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that the company intends to explore a
IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications
GlobeNewswire Inc.
Dec 15, 2025 9:05 PM GMT
Findings provide scientific insights into the contributions of IDO1 and PD-L1 vaccination to PD-1 blockade for the treatment of metastatic melanomaFive-year analysis of median progression free survival was 25.5 monthsThese results reinforce the poten